CD20-directed Antibody Interactions
- Name
- CD20-directed Antibody Interactions
- Accession Number
- DBCAT004203
- Description
Not Available
- Drugs
Drug Drug Description Rituximab A monoclonal anti-CD20 antibody used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis, pemphigus vulgaris, and rheumatoid arthritis. Ibritumomab tiuxetan A monoclonal anti-CD20 antibody used to treat B-cell non-Hodgkin's lymphoma via a conjugated radioactive isotope. Tositumomab A monoclonal anti-CD20 antibody used to treat B-cell non-Hodgkin's lymphoma via a conjugated radioactive isotope. Ofatumumab An anti-CD20 antibody used for the treatment of chronic lymphocytic leukemia (CLL) in selected patients with certain treatment histories and responsiveness to anticancer medications. Obinutuzumab An antineoplastic CD20 antibody used to treat untreated chronic lymphocytic leukemia in combination with chlorambucil. Ocrelizumab A CD20 specific monoclonal antibody used to treat relapsing remitting multiple sclerosis. Mosunetuzumab A humanized anti-CD20/CD3 bispecific antibody used to treat relapsed or refractory follicular lymphoma. Epcoritamab A bispecific CD20-directed CD3 T-cell engager used to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adults. - Drugs & Drug Targets